Literature DB >> 1837361

[Epilepsy seizures in HIV infection. 52 cases].

F Bartolomei1, P Pellegrino, C Dhiver, R Quilichini, J A Gastaut, J L Gastaut.   

Abstract

Fifty-two patients at various stages of human immunodeficiency virus (HIV) infection who had one or several epileptic seizures in the course of that disease were retrospectively studied from 1985 to 1990. Thirty-five percent of these patients were in overt clinical AIDS at the time of the seizure(s). AIDS was revealed by a seizure in 2 cases. Generalized seizures were observed in 71 percent of the patients, and partial seizures in 29 percent. Electroencephalograms showed signs of brain irritation in only 19 percent of the cases. The cause of epileptic seizure(s) could be determined in 36 patients: cerebral toxoplasmosis in 23 cases; progressive multifocal leucoencephalitis in 2 cases; HIV encephalopathy in 3 cases; iatrogenic cause in 4 cases; meningoencephalitis in 3 cases and neurosyphilis in 1 case. No cause other than HIV infection was found in 16 patients. These findings confirm those of previous studies. In about one-third of AIDS patients epileptic seizures are the only clinical manifestation of viral central nervous system infection.

Entities:  

Mesh:

Year:  1991        PMID: 1837361

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

Review 1.  Human immunodeficiency virus type 1 infection of the brain.

Authors:  W J Atwood; J R Berger; R Kaderman; C S Tornatore; E O Major
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 2.  Special populations: the management of seizures in HIV-positive patients.

Authors:  Paul Mullin; Gary Green; Rohit Bakshi
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

3.  Clinical features of seizures in patients with human immunodeficiency virus infection.

Authors:  Hyun Kyung Kim; Bum Sik Chin; Hyoung-Shik Shin
Journal:  J Korean Med Sci       Date:  2015-05-13       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.